General concern about a potentially higher risk of COVID-19 amomg patients with inflammatory skin diseases such as HS, under treatment with biologics has promoted a number of rports in the scientific literature.
Hidradenitis suppurativa and adalimumab in the COVID-19 era / Marzano A.V.; Moltrasio C.; Genovese G.; Muratori S.; Dapavo P.; Fabbrocini G.; Patrizi A.; Sechi A.; Micali G.; Pellegrino M.; Gisondi P.; Dini V.; Bianchi L.; Fania L.; Offidani A.; Prignano F.; Atzori L.; Miraglia E.; Cannavo S.P.; Bettoli V.; Stingeni L.; Balestri R.; Venturini M.; Peris K.. - In: EUROPEAN JOURNAL OF DERMATOLOGY. - ISSN 1167-1122. - STAMPA. - 30:(2020), pp. 748-749. [10.1684/ejd.2020.3927]
Hidradenitis suppurativa and adalimumab in the COVID-19 era
Genovese G.;Pellegrino M.;Offidani A.;Prignano F.;Atzori L.;Balestri R.;
2020
Abstract
General concern about a potentially higher risk of COVID-19 amomg patients with inflammatory skin diseases such as HS, under treatment with biologics has promoted a number of rports in the scientific literature.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
